Genetic capsid modifications allow efficient re-targeting of adeno- associated virus type 2

Nature Medicine

Volumn 5, Issue 9, 1999, Pages 1052-1056

  Girod, Anne ^a   Ried, Martin ^a   Wobus, Christiane ^c   Lahm, Harald ^a   Leike, Kristin ^a   Kleinschmidt, Jürgen ^c   Deléage, Gilbert ^d   Hallek, Michael ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS CAPSID;

AMINO ACID SEQUENCE; BINDING, COMPETITIVE; CAPSID; DEPENDOVIRUS; HEPARIN; HUMANS; INTEGRINS; LAMININ; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MUTATION; OLIGOPEPTIDES; RECEPTORS, VIRUS; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VIRUS ASSEMBLY;

EID: 0032870158     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/12491     Document Type: Article

References (24)

1. Kotin, R.M. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene Ther. 5, 793-801 (1994).
2. Hallek, M. et al. Recombinant adeno-associated virus vectors. JDrugs 1, 561-573 (1998).
3. Mizukami, H., Young, M.S. & Brown, K.E. Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology 217, 121-130 (1996).
4. Summerford, C. & Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445 (1998).
5. Summerford, C. Bartlett, J.S. & Samulski, R.J. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nature Med. 5, 78-82 (1999).
6. Qing, K. et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Med. 5, 71-77 (1999).
7. Hermonat, P.L., Labow, M.A., Wright, R., Berns, K.I. & Muzyczka, N. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J. Virol. 51, 329-339 (1984).
8. Tratschin, J.D., Miller, I.L. & Carter, B.J. Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J. Virol. 51, 611-619 (1984).
9. Ruffing, M., Heid, H. & Kleinschmidt, J.A. Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif. J. Gen. Virol. 75, 3385-3392 (1994).
10. Tsao, J. et al. The three-dimensional structure of canine parvovirus and its functional implications. Science 251, 1456-1464 (1991).
11. Geourjon, C. & Deléage, G. OPM: a self-optimized method for protein secondary structure prediction. Protein Eng. 7, 157-164 (1994).
12. Thompson, J.D., Higgins, D.G. & Gibson, T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research 22, 4673-4680 (1994).
13. Aumailley, M., Gerl, M., Sonnenberg, A., Deutzmann, R. & Timpl, R. Identification of the Arg-Gly-Asp sequence in laminin A chain as a latent cell-binding site being exposed in fragment P1. FEBS Lett. 262, 82-86 (1990).
14. White, J.M. Integrins as virus receptors. Curr. Biol. 3, 596-599 (1993).
15. Valsesia-Wittmann, S. et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68, 4609-4619 (1994).
16. Wistuba, A., Kern, A., Weger, S., Grimm, D. & Kleinschmidt, J.A. Subcellular compartimentalization of adeno-associated virus type 2 assembly. J. Virol. 71, 1341-1352 (1997).
17. Stewart, P.L. et al. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J. 16, 1189-1198 (1997).
18. Yang, Q. et al. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther. 9, 1929-1937 (1998).
19. z antibody. Nat. Biotech. 17, 181-186 (1999).
20. Smith, T.F. & Waterman, M.S. Identification of common molecular subsequences. J. Mol. Biol. 147, 195-197 (1981).
21. Kabsch, W. & Sander, C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637 (1983).
22. Samulski, R.J., Chang, L.S. & Shenk, T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61, 3096-3101 (1987).
23. Chiorini, J.A. et al. High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum. Gene Ther. 6, 1531-1541 (1995).
24. Carrel, S., Sordat, B. & Merenda, C. Establishment of a cell line (Co-115) from a human colon carcinoma transplanted into nude mice. Cancer Res. 36, 3978-3984 (1976).